Literature DB >> 27443518

Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.

Jen-Chieh Lee1, Sheng-Yao Su2,3, Chun A Changou4,5, Rong-Sen Yang6, Keh-Sung Tsai7, Michael T Collins8, Eric S Orwoll9, Chung-Yen Lin2, Shu-Hwa Chen2, Shyang-Rong Shih7, Cheng-Han Lee10, Yoshinao Oda11, Steven D Billings12, Chien-Feng Li13, G Petur Nielsen14, Eiichi Konishi15, Fredrik Petersson16, Thomas O Carpenter17, Kesavan Sittampalam18, Hsuan-Ying Huang19, Andrew L Folpe20.   

Abstract

Phosphaturic mesenchymal tumors typically cause paraneoplastic osteomalacia, chiefly as a result of FGF23 secretion. In a prior study, we identified FN1-FGFR1 fusion in 9 of 15 phosphaturic mesenchymal tumors. In this study, a total of 66 phosphaturic mesenchymal tumors and 7 tumors resembling phosphaturic mesenchymal tumor but without known phosphaturia were studied. A novel FN1-FGF1 fusion gene was identified in two cases without FN1-FGFR1 fusion by RNA sequencing and cross-validated with direct sequencing and western blot. Fluorescence in situ hybridization analyses revealed FN1-FGFR1 fusion in 16 of 39 (41%) phosphaturic mesenchymal tumors and identified an additional case with FN1-FGF1 fusion. The two fusion genes were mutually exclusive. Combined with previous data, the overall prevalence of FN1-FGFR1 and FN1-FGF1 fusions was 42% (21/50) and 6% (3/50), respectively. FGFR1 immunohistochemistry was positive in 82% (45/55) of phosphaturic mesenchymal tumors regardless of fusion status. By contrast, 121 cases of potential morphologic mimics (belonging to 13 tumor types) rarely expressed FGFR1, the main exceptions being solitary fibrous tumors (positive in 40%), chondroblastomas (40%), and giant cell tumors of bone (38%), suggesting a possible role for FGFR1 immunohistochemistry in the diagnosis of phosphaturic mesenchymal tumor. With the exception of one case reported in our prior study, none of the remaining tumors resembling phosphaturic mesenchymal tumor had either fusion type or expressed significant FGFR1. Our findings provide insight into possible mechanisms underlying the pathogenesis of phosphaturic mesenchymal tumor and imply a central role of the FGF1-FGFR1 signaling pathway. The novel FN1-FGF1 protein is expected to be secreted and serves as a ligand that binds and activates FGFR1 to achieve an autocrine loop. Further study is required to determine the functions of these fusion proteins.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27443518     DOI: 10.1038/modpathol.2016.137

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  44 in total

1.  Two nuclear localization signals required for transport from the cytosol to the nucleus of externally added FGF-1 translocated into cells.

Authors:  Jørgen Wesche; Jedrzej Małecki; Antoni Wiedłocha; Maryam Ehsani; Ewa Marcinkowska; Trine Nilsen; Sjur Olsnes
Journal:  Biochemistry       Date:  2005-04-26       Impact factor: 3.162

2.  FN1-EGF gene fusions are recurrent in calcifying aponeurotic fibroma.

Authors:  Florian Puls; Jakob Hofvander; Linda Magnusson; Jenny Nilsson; Elaine Haywood; Vaiyapuri P Sumathi; D Chas Mangham; Lars-Gunnar Kindblom; Fredrik Mertens
Journal:  J Pathol       Date:  2016-03       Impact factor: 7.996

3.  The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex.

Authors:  Zhengliang L Wu; Lijuan Zhang; Tomio Yabe; B Kuberan; David L Beeler; Andre Love; Robert D Rosenberg
Journal:  J Biol Chem       Date:  2003-02-25       Impact factor: 5.157

4.  Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours.

Authors:  I el-Hariry; M Pignatelli; N Lemoine
Journal:  J Pathol       Date:  1997-01       Impact factor: 7.996

5.  Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma.

Authors:  N H Chow; K S Cheng; P W Lin; S H Chan; W C Su; Y N Sun; X Z Lin
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

6.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets.

Authors:  N Weidner; D Santa Cruz
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

7.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

Authors:  Sam Behjati; Patrick S Tarpey; Nadège Presneau; Susanne Scheipl; Nischalan Pillay; Peter Van Loo; David C Wedge; Susanna L Cooke; Gunes Gundem; Helen Davies; Serena Nik-Zainal; Sancha Martin; Stuart McLaren; Victoria Goodie; Ben Robinson; Adam Butler; Jon W Teague; Dina Halai; Bhavisha Khatri; Ola Myklebost; Daniel Baumhoer; Gernot Jundt; Rifat Hamoudi; Roberto Tirabosco; M Fernanda Amary; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Adrienne M Flanagan
Journal:  Nat Genet       Date:  2013-10-27       Impact factor: 38.330

8.  Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.

Authors:  Mouhammed Amir Habra; Camilo Jimenez; Su-Chen Eileen Huang; Gilbert J Cote; William A Murphy; Robert F Gagel; Ana O Hoff
Journal:  Endocr Pract       Date:  2008-12       Impact factor: 3.443

9.  Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors.

Authors:  Maria P Yavropoulou; Nikolina Gerothanasi; Athanasios Frydas; Evangelia Triantafyllou; Chris Poulios; Prodromos Hytiroglou; Panagiotis Apostolou; Ioannis Papasotiriou; Symeon Tournis; Isaak Kesisoglou; John G Yovos
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-05-27

10.  Osteocyte-specific deletion of Fgfr1 suppresses FGF23.

Authors:  Zhousheng Xiao; Jinsong Huang; Li Cao; Yingjuan Liang; Xiaobin Han; Leigh Darryl Quarles
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more
  38 in total

1.  Giant cell tumor of soft tissue is genetically distinct from its bone counterpart.

Authors:  Jen-Chieh Lee; Cher-Wei Liang; Christopher Dm Fletcher
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia.

Authors:  Sri Harsha Tella; Hayet Amalou; Bradford J Wood; Richard Chang; Clara C Chen; Cemre Robinson; Michelle Millwood; Lori C Guthrie; Sheng Xu; Elliot Levy; Venkatesh Krishnasamy; Rachel I Gafni; Michael T Collins
Journal:  J Bone Miner Res       Date:  2017-09-06       Impact factor: 6.741

Review 3.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

4.  Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms.

Authors:  Yu-Chien Kao; Uta Flucke; Astrid Eijkelenboom; Lei Zhang; Yun-Shao Sung; Albert J H Suurmeijer; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-04       Impact factor: 6.394

Review 5.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

6.  Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia.

Authors:  Iris R Hartley; Carole B Miller; Georgios Z Papadakis; Clemens Bergwitz; Jaydira Del Rivero; Jenny E Blau; Pablo Florenzano; Jason A Berglund; Jing Tassone; Kelly L Roszko; Susan Moran; Rachel I Gafni; Randi Isaacs; Michael T Collins
Journal:  N Engl J Med       Date:  2020-09-09       Impact factor: 91.245

Review 7.  Phosphaturic mesenchymal tumors: what an endocrinologist should know.

Authors:  J M Boland; P J Tebben; A L Folpe
Journal:  J Endocrinol Invest       Date:  2018-02-14       Impact factor: 4.256

Review 8.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

9.  Clinicopathologic and molecular features of six cases of phosphaturic mesenchymal tumor.

Authors:  Lulu Sun; Carina Dehner; Jason Kenney; Samantha M McNulty; Xiaopei Zhu; John D Pfeifer; Horacio M Maluf; John S A Chrisinger
Journal:  Virchows Arch       Date:  2020-11-05       Impact factor: 4.064

10.  A molecular study of synovial chondromatosis.

Authors:  Narasimhan P Agaram; Lei Zhang; Brendan C Dickson; David Swanson; Yun-Shao Sung; David M Panicek; Meera Hameed; John H Healey; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-10-18       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.